SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
ARTIGO
Inglês
Agradecimentos: The work was supported by Celgene Future Leaders of Hematology Award and Cleveland Clinic Institutional Seed Support (RVT); National Institutes of Health grants R01-HL082983 (JPM), U54-RR019391 (JPM and MAS) and K24-HL077522 (JPM); and a charitable donation from Robert Duggan Cancer...
Agradecimentos: The work was supported by Celgene Future Leaders of Hematology Award and Cleveland Clinic Institutional Seed Support (RVT); National Institutes of Health grants R01-HL082983 (JPM), U54-RR019391 (JPM and MAS) and K24-HL077522 (JPM); and a charitable donation from Robert Duggan Cancer Research Foundation. The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (contract no. N01-HC-25195). This manuscript was not prepared in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University or NHLBI
Fechado
DOI: https://doi.org/10.1038/leu.2011.232
Texto completo: https://www.nature.com/articles/leu2011232
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
Fontes
Leukemia Vol. 26 (Mar., 2012), p. 542-545 |